New Delhi: flu virus A virus that had infected millions of people, especially children, mysteriously disappeared from the face of the Earth. Experts believe it should be removed because they are convinced it is gone. vaccine entire.
This virus, known as the Yamagata strain, was one of four flu viruses commonly included in the annual flu virus. influenza Vaccination. However, in March 2020, it went completely quiet in line with the global situation. Closure Due to COVID-19 global epidemic of infectious diseasesReport METRO.
Thanks to preventive measures such as wearing masks and social distancing to prevent the spread of COVID-19, flu cases have reached an all-time low. In fact, one of the flu viruses, the Yamagata strain, has been completely eradicated. The Yamagata lineage belongs to the Influenza B family tree, which also includes the Victoria lineage. Although these viruses are not the most lethal or rapidly evolving, they tend to cause more illness in children, who are not as exposed to the virus as adults.
In contrast, influenza A viruses, such as H1N1, are of more concern and have the potential to cause pandemics. For example, the 1918 ‘pandemic’ epidemic killed an estimated 50 million people. The Yamagata strain, a type B virus, has never caused an epidemic. Therefore, the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO) have agreed that seasonal flu vaccines no longer need to include it.
The FDA strongly recommended that influenza vaccine manufacturers eliminate B/Yamagata lineage viruses starting with the upcoming 2024-2025 influenza season. The transition from quadrivalent to trivalent vaccines will reduce the number of flu strains covered by the vaccine from quadrivalent to trivalent. The hope is that the changes will allow manufacturers to increase production capacity and provide more doses.
Dr. Hana El Sahly, chair of the FDA Advisory Committee, emphasized the importance of not vaccinating individuals against viruses that have not been in circulation for several years. However, some members of the pharmaceutical industry argued that manufacturers would need time to transition to new vaccine formulations. The government's Green Book also states that the trivalent vaccine is clinically appropriate.
In conclusion, the disappearance of the Yamagata influenza virus has led to a recommendation to remove it from the seasonal flu vaccine. This decision was based on the fact that, unlike the influenza A virus, this virus did not cause a pandemic. Although some challenges may arise during the transition to a trivalent vaccine, this change is expected to increase vaccine production. The ultimate goal is to ensure that vaccines are effective against the viruses currently in circulation that pose the greatest threat to public health.
This virus, known as the Yamagata strain, was one of four flu viruses commonly included in the annual flu virus. influenza Vaccination. However, in March 2020, it went completely quiet in line with the global situation. Closure Due to COVID-19 global epidemic of infectious diseasesReport METRO.
Thanks to preventive measures such as wearing masks and social distancing to prevent the spread of COVID-19, flu cases have reached an all-time low. In fact, one of the flu viruses, the Yamagata strain, has been completely eradicated. The Yamagata lineage belongs to the Influenza B family tree, which also includes the Victoria lineage. Although these viruses are not the most lethal or rapidly evolving, they tend to cause more illness in children, who are not as exposed to the virus as adults.
In contrast, influenza A viruses, such as H1N1, are of more concern and have the potential to cause pandemics. For example, the 1918 ‘pandemic’ epidemic killed an estimated 50 million people. The Yamagata strain, a type B virus, has never caused an epidemic. Therefore, the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO) have agreed that seasonal flu vaccines no longer need to include it.
The FDA strongly recommended that influenza vaccine manufacturers eliminate B/Yamagata lineage viruses starting with the upcoming 2024-2025 influenza season. The transition from quadrivalent to trivalent vaccines will reduce the number of flu strains covered by the vaccine from quadrivalent to trivalent. The hope is that the changes will allow manufacturers to increase production capacity and provide more doses.
Dr. Hana El Sahly, chair of the FDA Advisory Committee, emphasized the importance of not vaccinating individuals against viruses that have not been in circulation for several years. However, some members of the pharmaceutical industry argued that manufacturers would need time to transition to new vaccine formulations. The government's Green Book also states that the trivalent vaccine is clinically appropriate.
In conclusion, the disappearance of the Yamagata influenza virus has led to a recommendation to remove it from the seasonal flu vaccine. This decision was based on the fact that, unlike the influenza A virus, this virus did not cause a pandemic. Although some challenges may arise during the transition to a trivalent vaccine, this change is expected to increase vaccine production. The ultimate goal is to ensure that vaccines are effective against the viruses currently in circulation that pose the greatest threat to public health.